Proove® Biosciences CEO To Speak At 8th Annual Life Sciences CEO Forum
Brian Meshkin will moderate a panel on "Delivering on the Promise of Precision Medicine" and participate in a panel on "The Convergence of Technology & Healthcare"
IRVINE, Calif., March 23, 2017 /PRNewswire/ -- Proove® Biosciences, Inc. announces that its founder and Chief Executive Officer, Brian Meshkin, will join other C-level executives and experts as a panelist and moderator at the 8th Annual Life Sciences CEO Forum sponsored by Q1 Productions this week, March 23-24, 2017 in San Diego, California.
On Friday morning, Brian Meshkin will moderate a panel entitled, "Delivering on the Promise of Precision Medicine: Analysis of Impact on the Life Science Industry." This panel will include distinguished participants, including Dr. Thierry Dervieux, Chief Scientific Officer of Exagen Diagnostics; Brady Davis, Chief Strategy Officer for DNA Nexus; and Alex Dickinson, Senior Vice President of Strategic Initiatives at Illumina. On this panel, experts will discuss how government research efforts are shaping discoveries related to therapeutic biomarkers and diagnostics, how these technologies can influence research and clinical care, and the regulatory and reimbursement challenges.
On Friday afternoon, Meshkin will participate on a panel entitled, "The Convergence of Technology & Healthcare." This panel will be led by venture capitalist Luke Lee, a principal at Asset Management Ventures, and include healthcare attorney, Stephanie Trunk, Esq. from Arent Fox LLP; Chase Hensel, Co-Founder and CEO of digital therapeutics company Welkin Health; and Felix Frueh, CEO of Intellos Health. In this panel, experts will discuss digital health trends, the impact of collecting data and how to use it, legal implications, and experiences from market utilization.
"It's an honor to participate in such an exclusive event which brings together leaders in the field. Proove is strongly positioned as the leader in precision medicine for pain. Every day, we demonstrate the positive impact of technology as clinicians 'proove' the diagnosis and treatment of patients in pain using our technology to provide better outcomes. In the pathway of progress, there are always skeptics and naysayers to step over, and so it's refreshing to hear the insights and experiences from my peers in the arena. Hopefully, I can share what we've learned from our success and failures to help others who are trying to make a positive impact in healthcare," explains Proove CEO Brian Meshkin.
About Proove Biosciences: Proove® Biosciences is the leader in precision medicine for the condition that lies at the nexus of health – pain. Proove® delivers precision medicine solutions for the nation's most prevalent and expensive health condition by investing heavily in research that has won awards from leading medical societies and been published in peer-reviewed journals. Discovered by NIH-funded scientists, Proove® has translated into clinical practice the genetic variants and phenotypic factors contributing to pain sensitivity and chronic pain risk. Proove®'s medical advisory board is led by those NIH-funded researchers and the company has licensed some of its technology from leading academic centers, such as the University of North Carolina at Chapel Hill, the University of Utah, and other institutions. Positioned as The Healthcare Decision Company,™ Proove®'s patented technology platform combines genetic, clinical, environmental and lifestyle information to help clinicians better evaluate pain sensitivity, assess risk for opioid use disorder, predict therapeutic response to pain medications, and assess drug metabolism for the many medications used in chronic pain patients. Based in Irvine, California, Proove® has been recognized on the Inc. 500 and the Deloitte Technology Fast500 as one of the fastest growing companies in North America. For more information, please visit www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).
SOURCE Proove Biosciences, Inc.
Share this article